Topic: Absolute Risk Reduction

A paper published in The Lancet discusses the difference between relative risk reduction and absolute risk reduction in COVID-19 vaccines. The data suggests that while relative efficacy is high, the absolute risk reduction for vaccines like Pfizer and Moderna is approximately 1%, leading to questions about the necessity of universal vaccination.

A peer-reviewed study published in the British Medical Journal suggests that COVID-19 vaccines may sensitize recipients to more severe disease through neutralizing antibodies. The data indicates that while relative risk reduction is high, the absolute risk reduction for Pfizer and Moderna vaccines is only between 0.7% and 1.1%. This discrepancy suggests the actual benefit to the average individual is much lower than publicly reported.